Jun 22, 2026 08:30AM
Feb 23, 2026 07:00AM
Feb 23, 2026 07:00AM
Apr 30, 2025 04:49AM
Aug 8, 2024 07:00AM
Aug 8, 2023 07:02AM
Aug 8, 2023 07:00AM Foghorn Therapeutics Announces Chief Medical Officer Succession
Jun 5, 2023 07:00AM
Jun 5, 2023 07:00AM
May 8, 2023 07:00AM
Apr 24, 2023 08:23AM
Apr 24, 2023 07:03AM
Apr 24, 2023 07:00AM
Apr 24, 2023 07:00AM Foghorn Therapeutics Provides an Update on FHD-609
Mar 9, 2023 07:00AM
Mar 9, 2023 07:00AM
Jan 9, 2023 07:00AM
Jan 9, 2023 07:00AM
Nov 8, 2022 07:00AM
Nov 8, 2022 07:00AM
Aug 23, 2022 07:00AM Foghorn Therapeutics Inc. (FHTX) Announces FDA Clinical Hold Placed on FHD-286 Phase I Study
Aug 23, 2022 07:00AM
Aug 23, 2022 07:00AM
Aug 9, 2022 07:00AM
Aug 9, 2022 07:00AM
May 20, 2022 09:08AM
May 19, 2022 06:08PM
May 19, 2022 04:05PM Foghorn Therapeutics (FHTX) Phase 1 Study of FHD-286 Placed on Partial Clinical Hold
May 19, 2022 04:01PM
May 19, 2022 04:01PM
Feb 28, 2022 09:00AM
Dec 13, 2021 09:21AM
Aug 10, 2021 07:00AM
Aug 10, 2021 07:00AM
Jun 8, 2021 07:00AM Foghorn Therapeutics to Host Research & Development Day Webinar on June 15th
Jun 8, 2021 07:00AM
May 11, 2021 07:00AM
May 11, 2021 07:00AM
Mar 18, 2021 08:00AM
Mar 18, 2021 08:00AM
Dec 4, 2020 08:00AM
Dec 4, 2020 08:00AM Foghorn Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update

324,254 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All